Meiragtx Holdings Plc (MGTX) Stock Price, Quote & News

Company Profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RP...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 860 7985

Website: www.meiragtx.com

Address:

655 Third Avenue, Suite 1115, New York, United States

ErnieWorthing84 May. 13 at 12:26 PM

$MGTX We're also apparently at ASGCT, but in typical Meira fashion, no one mentioned it https://www.linkedin.com/posts/jeroenbastiaans_asgct-genetherapy-cellandgenetherapy-share-7460279747177037824-Don8?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA-izPIBXISQ360qmHAvSKAoz0ecqKOipGs

0 · Reply

ErnieWorthing84 May. 13 at 12:25 PM

$MGTX We're at BofA tonight, 8pm EST https://meiragtx.gcs-web.com/events/event-details/bofa-securities-2026-global-healthcare-conference

1 · Reply

ErnieWorthing84 May. 12 at 7:13 PM

$MGTX Worth rewatching this from minute 36:00 on XLRP, as a refresher... https://www.youtube.com/watch?v=RURpD77rc-0

2 · Reply

ErnieWorthing84 May. 12 at 6:12 PM

$MGTX https://x.com/davidalim/status/2054241160302838219

0 · Reply

jlemx May. 12 at 1:54 PM

$MGTX when mgtx at $100 ?

0 · Reply

Bogy99 May. 12 at 10:03 AM

$MGTX alrighty then. Looks like shorts took advantage of the recent stock issuance. Latest data shows 5.7+mm shares short. That’s the highest EVER!! Shorting a company with 2 potential (likely) commercial assets with 5+B (that’s a B, no typo) in peak sales seems like a really dumb thing to do. We even have earnings coming up this week or next. Those who short a stock that cured pediatric blindness ((LCA4) deserve a special place in Hell!! Sleep well dirt bags , your time is up !!

1 · Reply

SuperGreenToday May. 11 at 1:24 PM

$MGTX Share Price: $9.81 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.68 – $2.08 Target Zone: $2.87 – $3.51 Potential Upside: 61% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

slinghook67 May. 10 at 2:16 PM

$MGTX As we all know, MeiraGTx raised their peak annual revenue estimate for Xerostomia to $3.7b last month. Specific to the attached slide from their corporate presentation, I asked several AI apps what are peak sales estimates if their GT for Xerostomia became a "pipeline in a product" across the remaining 3 areas beyond radiation induced Xerostomia. Here are their respective responses, all of which are listed as a base case, not a bull case: Claude = $8B - $14B ChatGPT = $8B - $12B Gemini = $8B - $10B CoPilot = $7B - $9B Perplexity = $6.5B - $7.5B And this is for a single asset that Meira owns outright. And yet here we sit at an ~$800M valuation.....

2 · Reply

ErnieWorthing84 May. 8 at 5:55 PM

$MGTX https://www.wsj.com/health/healthcare/trump-planning-to-fire-fda-commissioner-marty-makary-34c072e2?st=roRGsz&reflink=desktopwebshare_permalink

2 · Reply

BigDaddy_LongTrades May. 8 at 4:00 PM

$MGTX in the next 6 months does anyone think $15 a share is realistic?

1 · Reply

MeiraGTx price target raised to $30 from $26 at Piper Sandler

JNJ

2026-04-17T13:19:37.000Z - 26 days ago

MeiraGTx price target raised to $24 from $16 at RBC Capital

2026-04-16T12:00:53.000Z - 27 days ago

MeiraGTx announces three-year data from Phase 1 AQUAx study

Apr 16, 2026, 8:00 AM EDT - 27 days ago

MeiraGTx Holdings Transcript: KOL event

Apr 16, 2026, 7:47 AM EDT - 27 days ago

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

2026-04-16T11:45:30.000Z - 27 days ago

MeiraGTx announces acquisition of bota-vec for treatment of XLRP

JNJ

Apr 16, 2026, 7:10 AM EDT - 27 days ago

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Apr 16, 2026, 7:00 AM EDT - 27 days ago

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

Apr 14, 2026, 8:30 AM EDT - 4 weeks ago

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

2026-04-01T11:59:11.000Z - 6 weeks ago

MeiraGTx price target lowered to $18 from $20 at Evercore ISI

2026-03-27T11:01:18.000Z - 6 weeks ago

MeiraGTx price target lowered to $26 from $30 at Piper Sandler

2026-03-27T10:26:11.000Z - 6 weeks ago

MeiraGTx price target raised to $16 from $14 at BofA

Mar 26, 2026, 8:00 AM EDT - 6 weeks ago

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

Mar 25, 2026, 11:00 AM EDT - 7 weeks ago

MeiraGTx Holdings Transcript: RBC Capital Markets Virtual Ophthalmology Conference

2026-02-03T13:16:56.000Z - 3 months ago

MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy

Feb 3, 2026, 8:00 AM EST - 3 months ago

ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

2026-01-06T15:25:58.000Z - 4 months ago

MeiraGTx price target lowered to $14 from $15 at BofA

2025-11-24T11:15:40.000Z - 6 months ago

MeiraGTx initiated with a Buy at H.C. Wainwright

Nov 20, 2025, 3:00 PM EST - 6 months ago

Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

2025-11-13T13:11:25.000Z - 6 months ago

MeiraGTx sees cash runway into 2H27

Nov 13, 2025, 8:00 AM EST - 6 months ago

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Nov 10, 2025, 9:10 AM EST - 6 months ago

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

LLY

Nov 10, 2025, 7:00 AM EST - 6 months ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Oct 21, 2025, 3:30 PM EDT - 7 months ago

MeiraGTx Holdings Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 7, 2025, 8:00 AM EDT - 7 months ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Aug 14, 2025, 8:00 AM EDT - 9 months ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

May 13, 2025, 4:30 PM EDT - 1 year ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 9, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 29, 2025, 7:11 AM EDT - 1 year ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Apr 3, 2025, 11:30 AM EDT - 1 year ago

MeiraGTx Holdings Transcript: RBC Inaugural Virtual Ophthalmology Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 1 year ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 8:00 AM EST - 1 year ago

MeiraGTx Holdings Transcript: Study Update

Feb 21, 2025, 6:30 AM EST - 1 year ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 8:30 AM EST - 1 year ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Sep 30, 2024, 1:00 PM EDT - 1 year ago

MeiraGTx Holdings Transcript: Chardan's 8th Annual Genetic Medicines Conference

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jun 12, 2024, 2:40 PM EDT - 2 years ago

MeiraGTx Holdings Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 15, 2024, 1:40 PM EDT - 2 years ago

MeiraGTx Holdings Transcript: BofA Securities Health Care Conference 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 29, 2024, 11:00 AM EDT - 2 years ago

MeiraGTx Holdings Transcript: Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit (Virtual)

Apr 24, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 3 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Transcript: Study Update

Jun 27, 2023, 7:30 AM EDT - 3 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 3 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 13, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Holdings Transcript: Study Update

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 4 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 3, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

Jun 28, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Holdings Transcript: Study Result

Jun 28, 2022, 7:00 AM EDT - 4 years ago

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

May 12, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

May 4, 2022, 4:01 PM EDT - 4 years ago

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

ErnieWorthing84 May. 13 at 12:26 PM

0 · Reply

ErnieWorthing84 May. 13 at 12:25 PM

$MGTX We're at BofA tonight, 8pm EST https://meiragtx.gcs-web.com/events/event-details/bofa-securities-2026-global-healthcare-conference

1 · Reply

ErnieWorthing84 May. 12 at 7:13 PM

$MGTX Worth rewatching this from minute 36:00 on XLRP, as a refresher... https://www.youtube.com/watch?v=RURpD77rc-0

2 · Reply

ErnieWorthing84 May. 12 at 6:12 PM

$MGTX https://x.com/davidalim/status/2054241160302838219

0 · Reply

jlemx May. 12 at 1:54 PM

$MGTX when mgtx at $100 ?

0 · Reply

Bogy99 May. 12 at 10:03 AM

1 · Reply

SuperGreenToday May. 11 at 1:24 PM

0 · Reply

slinghook67 May. 10 at 2:16 PM

2 · Reply

ErnieWorthing84 May. 8 at 5:55 PM

$MGTX https://www.wsj.com/health/healthcare/trump-planning-to-fire-fda-commissioner-marty-makary-34c072e2?st=roRGsz&reflink=desktopwebshare_permalink

2 · Reply

BigDaddy_LongTrades May. 8 at 4:00 PM

$MGTX in the next 6 months does anyone think $15 a share is realistic?

1 · Reply

ErnieWorthing84 May. 6 at 2:40 PM

$MGTX https://x.com/rachaelmbade/status/2051988874830688474

1 · Reply

ErnieWorthing84 May. 6 at 12:01 PM

$MGTX Will be surprised if Makary lasts the month.

0 · Reply

ErnieWorthing84 May. 5 at 8:40 PM

$MGTX Wellp https://x.com/l_e_whyte/status/2051705509724500299

1 · Reply

ErnieWorthing84 May. 4 at 3:17 PM

$MGTX https://www.bloomberg.com/news/features/2026-05-04/rfk-jr-s-embattled-fda-chief-on-thin-ice-over-chaos-and-strife

0 · Reply

waterlock May. 4 at 1:44 PM

$MGTX MeiraGTx Holdings(MGTX) Perceptive Advisors raised its stake in the gene therapy company to 11,742,117 shares. Perceptive Advisors did so through the purchase of 555,555 MeiraGTx shares on April 17 at a price of $9 per share pursuant to the company's underwritten public offering. the latest purchase, Perceptive Advisors continues to own a 12.6% stake in MeiraGTx's outstanding stock. Shares of MeiraGTx have gained approximately 14.6% in value in 2026.

0 · Reply

AimSmall May. 1 at 6:06 PM

$MGTX @ErnieWorthing84 @slinghook67 - curious what other companies you guys are invested in?

1 · Reply

ErnieWorthing84 May. 1 at 5:29 PM

$MGTX Lane remains open https://www.fiercebiotech.com/biotech/amgen-abandons-candidates-cancer-and-sjogrens-syndrome-after-ph-2-data-not-par?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=0316A4496778F6E

1 · Reply

ErnieWorthing84 Apr. 30 at 6:44 PM

$MGTX https://www.linkedin.com/posts/davidberrymdphd_theres-a-revolution-in-cancer-but-can-big-share-7455251334607511552-OL-j?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA-izPIBXISQ360qmHAvSKAoz0ecqKOipGs

1 · Reply

BigDaddy_LongTrades Apr. 29 at 9:50 PM

$MGTX Remember when we were at 11? That felt nice.

1 · Reply

MGTX Apr. 29 at 2:12 PM

$MGTX How low will the stock go? What’s your best guess? My guess is $7

1 · Reply

BillionerOfKing Apr. 29 at 2:04 PM

$MGTX Current Stock Price: $8.79 Contracts to trade: $10.0 MGTX May 15 2026 Call Entry: $0.81 Exit: $1.34 ROI: 65% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ErnieWorthing84 Apr. 28 at 12:12 PM

$MGTX https://finance.yahoo.com/sectors/healthcare/articles/profluent-lilly-partner-genetic-medicine-111848468.html

0 · Reply

Market Cap	916.48M
Revenue (ttm)	81.39M
Net Income (ttm)	-114.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.31%
Debt to Equity Ratio	-8.58

Volume	359,400
Avg Vol	775,368
Day's Range	N/A - N/A
Shares Out	92.57M
Stochastic %K	65%
Beta	1.23
Analysts	Strong Sell
Price Target	$27.88